PL2206719T3 - Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien - Google Patents
Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dienInfo
- Publication number
- PL2206719T3 PL2206719T3 PL10150763T PL10150763T PL2206719T3 PL 2206719 T3 PL2206719 T3 PL 2206719T3 PL 10150763 T PL10150763 T PL 10150763T PL 10150763 T PL10150763 T PL 10150763T PL 2206719 T3 PL2206719 T3 PL 2206719T3
- Authority
- PL
- Poland
- Prior art keywords
- diene
- methods
- androsta
- benzimidazole
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65739005P | 2005-03-02 | 2005-03-02 | |
EP10150763.0A EP2206719B1 (en) | 2005-03-02 | 2006-03-02 | Pharmaceutical composition comprising 3-beta-hydroxy-17-(1-h-benzimidazole-1-yl)androsta-5,16-diene |
EP06736460A EP1853619B1 (en) | 2005-03-02 | 2006-03-02 | 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene for use in the treatment of a prostate disease |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2206719T3 true PL2206719T3 (pl) | 2015-03-31 |
Family
ID=36941503
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06736460T PL1853619T3 (pl) | 2005-03-02 | 2006-03-02 | 3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty |
PL10150763T PL2206719T3 (pl) | 2005-03-02 | 2006-03-02 | Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06736460T PL1853619T3 (pl) | 2005-03-02 | 2006-03-02 | 3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty |
Country Status (22)
Country | Link |
---|---|
US (1) | US7875599B2 (pl) |
EP (2) | EP1853619B1 (pl) |
JP (2) | JP5130453B2 (pl) |
KR (1) | KR101380959B1 (pl) |
CN (2) | CN101155823A (pl) |
AT (1) | ATE482969T1 (pl) |
AU (1) | AU2006218711B2 (pl) |
BR (1) | BRPI0607523A2 (pl) |
CA (1) | CA2599953C (pl) |
DE (1) | DE602006017175D1 (pl) |
DK (2) | DK1853619T3 (pl) |
EA (1) | EA019560B1 (pl) |
ES (2) | ES2353413T3 (pl) |
HK (1) | HK1115387A1 (pl) |
IL (3) | IL185608A (pl) |
MX (1) | MX2007010593A (pl) |
NZ (1) | NZ561571A (pl) |
PL (2) | PL1853619T3 (pl) |
PT (2) | PT2206719E (pl) |
SI (2) | SI2206719T1 (pl) |
WO (1) | WO2006093993A1 (pl) |
ZA (1) | ZA200708106B (pl) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
ES2353413T3 (es) | 2005-03-02 | 2011-03-01 | University Of Maryland | 3-beta-hidroxi-17-(1h-bencimidazol-1-il)androsta-5,16-dieno para uso en el tratamiento de una enfermedad de la próstata. |
EP2167090A4 (en) | 2007-06-06 | 2010-08-25 | Univ Maryland | HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS |
WO2009114658A2 (en) * | 2008-03-12 | 2009-09-17 | University Of Maryland, Baltimore | Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer |
US20100048524A1 (en) * | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
WO2009120565A2 (en) | 2008-03-25 | 2009-10-01 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
WO2009129208A2 (en) * | 2008-04-14 | 2009-10-22 | University Of Maryland, Baltimore | Compositions and methods of inducing endoplasmic reticulum stress reponse |
EP2334686B1 (en) | 2008-08-28 | 2019-02-27 | President and Fellows of Harvard College | Cortistatin analogues and syntheses therof |
US20100105700A1 (en) * | 2008-10-28 | 2010-04-29 | Lead Therapeutics, Inc. | Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors |
GB2479693B (en) * | 2009-02-05 | 2014-04-09 | Tokai Pharmaceuticals Inc | Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia |
AU2010210422A1 (en) * | 2009-02-05 | 2011-08-18 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens |
WO2010091299A2 (en) * | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals | Novel combination cancer therapies |
GEP20156250B (en) | 2009-06-26 | 2015-02-25 | Novartis Ag | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
EP2461814A4 (en) * | 2009-08-07 | 2012-12-05 | Tokai Pharmaceuticals Inc | PROSTATE CANCER TREATMENT |
CA2780365A1 (en) * | 2009-11-13 | 2011-05-19 | Tokai Pharmaceuticals, Inc. | Mammalian metabolites of steroids |
WO2011066582A1 (en) * | 2009-11-30 | 2011-06-03 | Harbor Biosciences, Inc. | Anticancer compounds and screening method |
CN103108871B (zh) | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
EP2651916A2 (en) * | 2010-12-16 | 2013-10-23 | BioMarin Pharmaceutical Inc. | C-17-heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21 |
JP6002210B2 (ja) | 2011-04-28 | 2016-10-05 | ノバルティス アーゲー | 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤 |
JP2014523445A (ja) * | 2011-07-18 | 2014-09-11 | トーカイ ファーマシューティカルズ,インク. | 前立腺癌を処置するための新規な組成物及び方法 |
US20150005265A1 (en) * | 2011-12-22 | 2015-01-01 | Susan Stewart | Methods and compositions for combination therapy using p13k/mtor inhibitores |
EP4066841A1 (en) | 2013-03-14 | 2022-10-05 | University of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
WO2014165815A2 (en) * | 2013-04-04 | 2014-10-09 | University Of Maryland, Baltimore | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity |
MX2016001901A (es) | 2013-08-12 | 2016-10-13 | Tokai Pharmaceuticals Inc | Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno. |
AP2016009324A0 (en) | 2013-12-24 | 2016-07-31 | Harvard College | Cortistatin analogues and syntheses and uses thereof |
CN103694299A (zh) * | 2014-01-13 | 2014-04-02 | 中国药科大学 | 甾体类雄激素受体抑制剂、其制备方法及其医药用途 |
CN105732759A (zh) * | 2015-01-29 | 2016-07-06 | 苏州晶云药物科技有限公司 | (3β)-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯-3-醇的盐及其制备方法 |
EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
WO2017004411A1 (en) | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
WO2017066697A1 (en) | 2015-10-14 | 2017-04-20 | Dou Qingping | Treatments and diagnostics for cancers |
IT201600083406A1 (it) * | 2016-08-08 | 2018-02-08 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
IT201600121375A1 (it) * | 2016-11-30 | 2018-05-30 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
RU2749134C1 (ru) * | 2016-08-08 | 2021-06-04 | Индустриале Кимика С.Р.Л. | СПОСОБ ПОЛУЧЕНИЯ 3β-ГИДРОКСИ-17-(1Н-БЕНЗИМИДАЗОЛ-1-ИЛ)АНДРОСТА-5,16-ДИЕНА |
US20200369715A1 (en) * | 2018-02-13 | 2020-11-26 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase inhibitors and methods of use |
WO2019160890A1 (en) * | 2018-02-13 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase degraders and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA27440A (en) | 1887-08-16 | James T. Walsh | Art of making sheet metal cans, for packing meats, fruits, vegetables, etc. | |
CH621803A5 (pl) * | 1974-08-08 | 1981-02-27 | Siphar Sa | |
US5604213A (en) * | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
US5994335A (en) * | 1997-10-17 | 1999-11-30 | The University Of Maryland, Baltimore | 17-azolyl steroids useful as androgen synthesis inhibitors |
BRPI0412989A (pt) | 2003-07-29 | 2006-10-03 | Dompe Spa | combinação farmacêutica útil para mobilização de célula-tronco |
ES2353413T3 (es) * | 2005-03-02 | 2011-03-01 | University Of Maryland | 3-beta-hidroxi-17-(1h-bencimidazol-1-il)androsta-5,16-dieno para uso en el tratamiento de una enfermedad de la próstata. |
-
2006
- 2006-03-02 ES ES06736460T patent/ES2353413T3/es active Active
- 2006-03-02 ES ES10150763.0T patent/ES2528055T3/es active Active
- 2006-03-02 MX MX2007010593A patent/MX2007010593A/es active IP Right Grant
- 2006-03-02 EP EP06736460A patent/EP1853619B1/en active Active
- 2006-03-02 DK DK06736460.4T patent/DK1853619T3/da active
- 2006-03-02 NZ NZ561571A patent/NZ561571A/en not_active IP Right Cessation
- 2006-03-02 SI SI200631883T patent/SI2206719T1/sl unknown
- 2006-03-02 CA CA2599953A patent/CA2599953C/en active Active
- 2006-03-02 JP JP2007558143A patent/JP5130453B2/ja active Active
- 2006-03-02 EA EA200701872A patent/EA019560B1/ru not_active IP Right Cessation
- 2006-03-02 CN CNA2006800064632A patent/CN101155823A/zh active Pending
- 2006-03-02 BR BRPI0607523-1A patent/BRPI0607523A2/pt not_active IP Right Cessation
- 2006-03-02 AU AU2006218711A patent/AU2006218711B2/en active Active
- 2006-03-02 PL PL06736460T patent/PL1853619T3/pl unknown
- 2006-03-02 DK DK10150763.0T patent/DK2206719T3/en active
- 2006-03-02 PT PT101507630T patent/PT2206719E/pt unknown
- 2006-03-02 US US11/817,550 patent/US7875599B2/en active Active
- 2006-03-02 EP EP10150763.0A patent/EP2206719B1/en active Active
- 2006-03-02 DE DE602006017175T patent/DE602006017175D1/de active Active
- 2006-03-02 CN CN2013101036754A patent/CN103349664A/zh active Pending
- 2006-03-02 WO PCT/US2006/007143 patent/WO2006093993A1/en active Application Filing
- 2006-03-02 PT PT06736460T patent/PT1853619E/pt unknown
- 2006-03-02 SI SI200630861T patent/SI1853619T1/sl unknown
- 2006-03-02 PL PL10150763T patent/PL2206719T3/pl unknown
- 2006-03-02 AT AT06736460T patent/ATE482969T1/de active
- 2006-03-02 KR KR1020077022440A patent/KR101380959B1/ko not_active IP Right Cessation
-
2007
- 2007-08-30 IL IL185608A patent/IL185608A/en not_active IP Right Cessation
- 2007-09-20 ZA ZA200708106A patent/ZA200708106B/xx unknown
-
2008
- 2008-05-14 HK HK08105362.1A patent/HK1115387A1/xx not_active IP Right Cessation
-
2011
- 2011-01-06 IL IL210480A patent/IL210480A/en not_active IP Right Cessation
- 2011-01-06 IL IL210478A patent/IL210478A0/en unknown
-
2012
- 2012-09-06 JP JP2012196525A patent/JP5613206B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2206719T3 (pl) | Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien | |
HUS1600021I1 (hu) | MEK inhibitorok és módszerek azok felhasználására | |
HK1061354A1 (en) | Synthesis of 4-amino-thalidomide enantiomers | |
EP2966065A3 (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
TW200833695A (en) | Use of spiro-oxindole compounds as therapeutic agents | |
WO2009120565A3 (en) | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity | |
EP2044961A3 (en) | Phospholipid analogues for the treatment of cancers | |
WO2005077968A3 (en) | 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity | |
WO2005103010A3 (en) | Pyrazole derivatives useful for the treatment of cancer | |
WO2007045060A8 (en) | Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production | |
WO2008011539A3 (en) | Anesthetic compounds | |
CY1115910T1 (el) | ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE | |
TW200603812A (en) | D-homo-17-chlor-16(17)-ene steroids |